King Charles III returned to work Tuesday, less than a week after being hospitalized for side effects from his cancer treatment. The British monarch presided over an investiture ceremony at ...

along with Novo Nordisk’s FDA-approved oral GLP-1 receptor agonist semaglutide (Rybelsus) and Merck & Co.’s phase III PCSK9 inhibitor enlicitide decanoate (MK-0616). Whereas semaglutide and ...

The Company will present an expansive portfolio of products and solutions, designed to help oral health professionals enhance practice efficiency and the patient experience, and will offer ...

Let’s walk through what sets this approach apart in a crowded landscape of generic oral solutions. (Special Deal) Tap Now Here to Secure PurDentix with an Incredible Discount. PurDentix ...